Mead Johnson Wins the First Federal NEC Bellwether in Inman
On August 31, 2026, a unanimous federal jury in Chicago returned a defense verdict for Mead Johnson in Inman v. Mead Johnson, the first case in the preterm infant formula MDL (MDL-3026) to reach a federal jury. The jury found that the infant's death was caused by extreme prematurity, not by Enfamil. It is the first federal NEC bellwether tried to a verdict, and it leaves Mead Johnson without an adverse jury result in the litigation.
What we know
- The verdict
- A unanimous defense verdict for Mead Johnson, a Reckitt company, returned August 31, 2026.
- The case
- Inman v. Mead Johnson, the first federal bellwether in the preterm infant formula MDL (MDL-3026) to reach a jury, before Chief Judge Rebecca R. Pallmeyer in the Northern District of Illinois. Plaintiff Alexis Inman alleged that Enfamil caused the fatal NEC of her prematurely born son.
- What the jury found
- That the death resulted from extreme prematurity and the infant's high-risk status, not from Enfamil. The jury rejected the claim that Mead Johnson should have reformulated its products since 2015.
- The pattern
- Mead Johnson now has no adverse jury verdict in the NEC litigation. Earlier federal bellwethers against Abbott were dismissed before trial, and the Seventh Circuit affirmed one (Mar v. Abbott) on July 24, 2026.
- The company statement
- Mead Johnson said the verdict “affirms Mead Johnson's view that the science doesn't support the claims here or in the litigation more broadly.”
What's still unknown
- Whether it ends the litigation
- No. About 847 cases remain in the federal MDL, and thousands more sit in state courts on their own schedules.
- Whether it speaks to Abbott's cases
- Abbott makes a different product (Similac) and has its own record, including a $495 million state verdict it later settled and a separate $670 million inventory settlement. A Mead Johnson defense verdict does not resolve the Abbott claims.
- What the science shows
- Causation is contested and courts have split. A jury's finding in one case is not a scientific consensus.
- What happens next
- No further Mead Johnson trial date and no post-trial motions have been publicly reported as of this writing.
Key Takeaways
- A unanimous federal jury returned a defense verdict for Mead Johnson (Reckitt) on August 31, 2026 in Inman v. Mead Johnson
- It is the first federal NEC bellwether to reach a jury; earlier federal bellwethers against Abbott were dismissed before trial
- The jury found the death was caused by extreme prematurity, not Enfamil, and rejected the claim that the formula should have been reformulated since 2015
- Mead Johnson now has no adverse jury verdict in the litigation (Collins defense, Whitfield defense, Watson reversed)
- The result does not end the litigation: about 847 cases remain in the federal MDL, and the Abbott claims are on a separate track
What the jury decided
Inman was the first case in the federal NEC MDL to reach a jury. The earlier federal bellwethers, all against Abbott, were dismissed on summary judgment when the court applied the Daubert reliability standard strictly to the fit between the plaintiffs' general-causation experts and each infant's gestational age and weight; the Seventh Circuit affirmed one of those dismissals in Mar v. Abbott on July 24, 2026. Inman was different because it survived that pretrial gate in May 2026, the first federal NEC case in which a plaintiff's causation expert cleared the challenge, and so it went to trial. After a trial that began August 17, the jury returned a unanimous verdict for Mead Johnson on August 31. It found that the infant's death was caused by his extreme prematurity and high-risk status rather than by Enfamil, and it rejected the argument that the company should have reformulated its preterm products since 2015. Mead Johnson said the verdict “affirms Mead Johnson's view that the science doesn't support the claims here or in the litigation more broadly.”
Federal and state courts have gone different ways
The single most useful thing to understand about NEC formula litigation is that the courts have not spoken with one voice. In state courts, juries have returned large plaintiff verdicts, most prominently the $495 million awarded against Abbott in St. Louis and $70 million awarded in Cook County. In the federal MDL, the pattern has run the other way: the pretrial rulings favored the defense, and now the first case to reach a federal jury has produced a defense verdict. Mead Johnson specifically has not lost a jury verdict in this litigation. An earlier $60 million verdict against it in Watson was reversed on appeal under the learned-intermediary doctrine, and it won defense verdicts in Collins and Whitfield. Read the pattern rather than any single number. A defense verdict for Mead Johnson is a real and significant result, and it sits alongside very different outcomes against a different defendant in a different courtroom.
The Abbott settlement is a separate track
Days before the Inman verdict, Abbott agreed on August 20, 2026 to pay $670 million to settle roughly 2,000 NEC cases handled by three plaintiff firms. That is a partial, inventory settlement of Abbott claims, not a global resolution of the MDL, and it does not involve Mead Johnson. It is also distinct from the confidential settlement Abbott reached in the $495 million Gill case in mid-August. The two defendants are on visibly different paths right now: Abbott is resolving parts of its docket while Mead Johnson is trying cases and, so far, winning them.
This is general litigation reporting and not legal advice. A verdict in one case does not decide any other family's claim, and filing deadlines vary by state and by when an injury was discovered. Anyone weighing a claim should confirm which manufacturer's product was used, gather the medical records, and speak with a licensed attorney about their own situation.
Full NEC formula background, verdicts & appeals
For the complete overview, the verdict and appeal tracker, the federal and state split, and eligibility, visit the case hub.
Sources
- • U.S. District Court, Northern District of Illinois: MDL-3026 docket, Inman v. Mead Johnson (verdict August 31, 2026).
- • Mead Johnson / Reckitt, "Mead Johnson Welcomes Defense Verdict in Inman Case" (August 31, 2026).
- • Legal Newsline, "Jury sides with Mead Johnson in first federal baby formula trial" (September 2026).
- • Judicial Panel on Multidistrict Litigation: Pending MDL Dockets by Actions Pending (September 1, 2026).
Attorney Advertising. The information on this page is provided for general informational purposes only and does not constitute legal advice. No attorney-client relationship is created by accessing or using this content.
Every case is unique, and results depend on the specific facts and circumstances involved. Past settlement amounts and case outcomes do not guarantee similar results in your case. If you believe you have a legal claim, you should consult with a licensed attorney in your jurisdiction who can evaluate your specific situation.